Condition: SLE - Systemic Lupus Erythematosus · IIM- Idiopathic Inflammatory Myopathies · SSc-Systemic Sclerosis · Sponsor: CytoCares Inc
This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.
This description comes directly from the study's public registry record.
CEO · +86-021-50582090 · yingfeng.huang@cytocares.com
Always discuss trial participation with your own doctor first.
| Deyang People's Hospital | Deyang, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07193810